Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-HCT and GVHD Prophylaxis in HIV Patients with Hematologic Malignancies
NCT05470491Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, bortezomib, maraviroc in graft-versus-host disease (GVHD), sponsored by National Cancer Institute. Started Jan 2023; status: recruiting.
02
Drugs
cyclophosphamidebortezomibmaraviroc
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05470491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470491.